Regencell Bioscience

RGC

Market cap $8.37B

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC) and Camping World Holdings, Inc. (NYSE:CWH). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Regencell Bioscience looks like a risky bet. It's generated zero revenue for several years in a row.

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Though artificial intelligence (AI) has been the primary S&P 500 (^GSPC -0.69%) catalyst for nearly three years, it's not the only two-word phrase that'll perk up investors on Wall Street. Mentioning "stock splits" is another easy way to garner attention.

For more than three decades, investors have consistently had a next-big-thing technology or trend to captivate their attention and wallets. For instance, artificial intelligence (AI) has been a driving force for Wall Street's major stock indexes for almost three years.

Though artificial intelligence (AI) has been the hottest innovation on Wall Street for well over two years, it's not the only trend that's helped power Wall Street's major stock indexes to record-closing highs. Excitement surrounding stock splits in some of the market's most influential businesses has been pivotal in sending the broader market higher.

Since the S&P 500's bull market began in October 2022, no trend has provided a bigger lift to equities than the evolution of artificial intelligence (AI). In Sizing the Prize, the analysts at PwC estimated AI would bolster the worldwide economy to the tune of $15.7 trillion come 2030.

Regencell Bioscience Holdings Ltd. RGC, a Hong Kong-based biotech startup with no reported revenue, has gained more than 59,000% in 2025.

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Regencell Bioscience Holdings, a biotech company focused on herbal medicine, has gained over 400% on Monday and over 64,000% in the past year. This growth in stock price is despite the company not having any revenue so far.